Comparing the Efficacy of Cipram® and Its Iranian Generic Citalopram in patients with mixed-anxiety disorder

Comparing the Efficacy of 8 Week Treatment of Cipram® and Its Iranian Generic Citalopram in Patients with Mixed Anxiety-Depressive Disorder

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201405127202N8

Enrollment

Registered

2014-05-31

Start date

2013-04-04

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mixed anxiety-depressive disorder. Mental and behavioural disorders

Interventions

Intervention 1: Iranian citalopram 10 mg/day are administered for first 3 days. Then, the daily dose is increased to 20 mg or higher. Maximum daily dose is 40 mg. Intervention 2: Cipram® 10 mg/day are

Treatment - Drugs

Iranian citalopram 10 mg/day are administered for first 3 days. Then, the daily dose is increased to 20 mg or higher. Maximum daily dose is 40 mg.

Cipram® 10 mg/day are administered for first 3 days. Then, the daily dose is increased to 20 mg or higher. Maximum daily dose is 40 mg.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All subjects aged between 18 and 55 years who met the criteria for Mixed Anxiety-Depressive Disorder (MADD) based on the DSM-IV and have Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety (HAM-A) scores of less than 24. Exclusion criteria: History of other psychiatric disorders including personality disorders, mental retardation, organic brain syndrome, neurological disorders, unstable medical situations including cardiovascular, hepatic, renal, endocrine or hematological disorders, alcohol or drug dependence, having suicidal idea, pregnancy and lactation, underwent ECT within the previous six months before the initiation of the study, patients on other drugs that could affect depression or anxiety.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anxiety. Timepoint: at baseline, 4 and 8 weeks after starting medication. Method of measurement: using HAM-A scoring systems.;Depression. Timepoint: at baseline, 4 and 8 weeks after starting medication. Method of measurement: using HAM-D scoring systems.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Bagher Oghazian

Tehran University of Medical Sciences

oghazian@razi.tums.ac.ir+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026